Login to Your Account

Inotek, Genentech Enter Deal: Up To $600M-Plus For PARPs

By Randall Osborne

Tuesday, July 25, 2006
Inotek Pharmaceuticals Corp.'s Phase II poly-ADP polymerase (PARP) inhibitor program bagged the firm a potential $600 million-plus deal with Genentech Inc., which is paying the privately held company $20 million up front.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription